# Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Source: https://onco.cc/trials/nct06683703/  
OnCo record `nct06683703` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of utidelone and bevacizumab in lung cancer, run by Beijing Biostar Pharmaceuticals Co., Ltd., not yet recruiting.

## Summary

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases is a phase 2, randomised interventional study registered as NCT06683703 by Beijing Biostar Pharmaceuticals Co., Ltd., with a registry enrolment figure of 118 participants, started 2024-12-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Utidelone combined with Bevacizumab; Utidelone; Utidelone combined with Bevacizumab; Utidelone combined with Bevacizumab. Conditions listed: Non-small Cell Lung Cancer Patients with Brain Metastases. Primary outcome: Intracranial objective response rate (iORR) according to the RECIST 1.1.; Determining the Expansion Dose. Lung eligibility wording from the registry: "non-squamous non-small cell lung cancer (adenocarcinoma or adenocarcinoma component dominant) with brain parenchymal metastasis confirmed by histology or cytology, but unsuitable or refused local treatment/surgery;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06683703
- Phase: 2
- Setting: Phase II Clinical Trial on the Efficacy and Safety of Utidelone Combined with Bevacizumab in Patients with Non-small Cell Lung Cancer with Brain Metastases.
- Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT06683703: https://clinicaltrials.gov/study/NCT06683703

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Utidelone](https://onco.cc/drugs/utidelone/)
- companies: [Biostar Pharmaceuticals](https://onco.cc/companies/biostar-pharmaceuticals/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06683703.json